AlphAIalphai — Financial news for AI agents
BenzingaFEB 34 min read$ARMP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This article highlights 12 healthcare stocks experiencing significant price movements in Tuesday's pre-market session. It lists top gainers including Liminatus Pharma, CDT Equity, and DaVita, noting their percentage increases and market capitalizations. Conversely, it identifies key losers such as Armata Pharmaceuticals, Avanos Medical, and Kairos Pharma, detailing their respective percentage decreases and market values.

Original reporting
Benzinga · Benzinga Insights, Benzinga Staff Writer
Published Feb 3, 2026, 12:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 3, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
12 Health Care Stocks Moving In Tuesday's Pre-Market Session — source image
Source · Benzinga
Decision brief

The 30-second read

$ARMPNeutralMed
01

Why it matters

Pre-market activity can signal short-term trading opportunities but is often influenced by overnight news and lacks confirmation.

02

Market read

The pre-market session indicates sector momentum, with key stocks showing directional moves that could influence intraday trading.

03

What to watch

Broader market conditions, upcoming earnings reports, or sector-specific news could alter short-term trajectories.

Timing: Immediate (pre-market session)

Background

The article summarizes pre-market movements in healthcare stocks, highlighting top gainers and losers.

Company-level read

Ticker impact

$ARMPNeutralMedium confidence
Context

Low relevance due to minimal sentiment impact and limited movement in pre-market session.

Expected impact

Minor decline expected, potential range-bound movement.

Evidence & confidence

The small percentage change and neutral sentiment suggest limited short-term impact, but ongoing news or broader market trends could influence the stock.

$CDTNeutralLow confidence
Context

Moderate relevance; details on percentage gains are not specified, but inclusion indicates some market activity.

Expected impact

Uncertain; likely limited short-term movement unless additional news emerges.

Evidence & confidence

Lack of detailed data reduces confidence in predicting significant price movements.

Market effects

Sector

Positive momentum in healthcare sector stocks could boost related life sciences and medical services stocks.

Regional

Limited; activity appears confined to specific stocks without broader regional implications.

Global

Low; news pertains to specific pre-market movements rather than global trends.

Counterpoint

What could challenge this read

Pre-market gains may be temporary; some stocks could revert to mean or face profit-taking.

Key entities

  • Company
    Liminatus Pharma

    A pharmaceutical company experiencing significant pre-market gains.

  • Company
    DaVita

    A healthcare services provider with notable pre-market activity.

  • Company
    Armata Pharmaceuticals

    A biotech firm showing minor pre-market decline.

  • Company
    CDT Equity

    An entity with moderate pre-market activity, specific details limited.

Read at source← All news

Related articles

AUG 12
$ARMPMedAI 8/10

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.

prnewswire.com6 min
AUG 12
$ARMPMed

Armata Pharmaceuticals, Inc. (ARMP): Results of Operations and Financial Condition

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 armp-20260812xex99d1.htm EX-99.1 Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update ​ LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “C

SEC EDGAR 8-K6 min
JUL 20
$ARMPMedAI 8/10

Why Is Armata Pharma Stock Gaining Monday? - Armata Pharmaceuticals (AMEX:ARMP)

Armata Pharmaceuticals said it submitted the complete Phase 3 protocol for its AP-SA02 multi-phage therapy to the FDA, addressing End-of-Phase 2 feedback, and completed four engineering runs at its Los Angeles cGMP facility. The Phase 3 superiority study is planned to start in 2H 2026. The company received a $2.5M DoD continuation award. ARMP shares were up 10.27% to $4.97.

benzinga.com4 min
JUL 13
$ARMPMed

Armata Gets FDA Agreement On Pediatric Plan For AP-SA02 In SAB

Armata Pharmaceuticals (ARMP) said the U.S. FDA agreed to its Initial Pediatric Study Plan for AP-SA02 in pediatric complicated Staphylococcus aureus bacteremia. The iPSP sets a framework to defer pediatric work until adult Phase 3 data, expected to start in H2 2026, then run a single multicenter open-label pediatric trial. ARMP shares closed July 10 at $4.26.

rttnews.com3 min
JUN 22
$CDTMed

Why Is CDT Equity Stock Surging On Monday? - CDT Equity (NASDAQ:CDT)

CDT Equity (NASDAQ:CDT) rose in premarket trading after the company said it received new funding tied to Sarborg Ltd. The report states the transaction was completed at $125,000 per share, implying a fully diluted Sarborg valuation of about $638.3 million. Proceeds are earmarked for SarborgQ launch and development, including its quantum computing and AI platform.

benzinga.com4 min
JUN 16
$CDTMed

CDT Equity Announces Debt Update and New Loan Facility

CDT Equity Inc. (Nasdaq: CDT) said it restructured debt by repaying all amounts due under its Loan Notes with Alliance Global Partners and Ascent Partners, eliminating more than $6.3 million of legacy financing obligations. It also entered a new loan agreement with JJ Astor for up to $1.46 million; the first tranche was about $268k, with the remainder subject to conditions in June 2026.

manilatimes.net3 min